DV
Dividend Vision

BBOT — BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Total return is -9.4% over the past year, 33.6 points behind SPY at 24.2%. Its deepest 1-year drawdown was 48.1%.

BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company developing small-molecule cancer therapeutics, including programs targeting KRAS mutations and HER2+ breast cancer currently in Phase I trials. The company does not currently distribute dividends. This security appeals to investors with high risk tolerance seeking exposure to early-stage oncology drug development.

BBOT key facts

Asset type
Stock
Asset class
Equity
Inception date
08/07/2025
Last close
$9.06
Market cap
$685,716,864
Average volume
227500.0
Beta
0.388
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.92